摘要
目的探讨程序性细胞死亡蛋白1(programmed cell death protein 1,PD-1)单抗联合化学药物治疗(以下简称化疗)在局部晚期非小细胞肺癌新辅助治疗中的疗效和安全性。方法回顾性分析2021年6月至2023年6月于首都医科大学附属北京友谊医院胸外科43例接受新辅助免疫治疗联合化疗的局部晚期(ⅡB~ⅢB)非小细胞肺癌患者的临床资料,评估其影像学及病理学疗效,并观察免疫相关不良反应。结果影像学疗效评价显示客观缓解率为76.7%,疾病控制率为93.0%。34例(79.1%)接受手术的患者中,R0切除率97.1%、完全病理缓解率为29.4%、主要病理缓解率为55.9%。1~2级免疫相关不良反应发生率为67.4%,3级及以上不良反应发生率为7.0%。结论新辅助PD-1单抗联合化疗治疗非小细胞肺癌疗效显著,病理缓解率及R0切除率高,免疫相关不良反应及手术并发症在可接受范围内,安全性较高。
Objective To investigate the efficacy and safety of programmed cell death protein 1(PD-1)inhibitors combined with chemotherapy in neoadjuvant treatment for locally advanced non-small cell lung cancer(NSCLC).Methods A retrospective analysis was conducted on clinical data of 43 patients with locally advanced(ⅡB~ⅢB)non-small cell lung cancer who received neoadjuvant immunotherapy combined with chemotherapy in the Department of Thoracic Surgery,Beijing Friendship Hospital from June 2021 to June 2023.The radiological and pathological efficacy were evaluated,meanwhile immune-related adverse events were observed.Results The evaluation of radiological efficacy showed an objective response rate of 76.7%and a disease control rate of 93.0%.Among the 34 patients(79.1%)who underwent surgery,the R0 resection rate was 97.1%,the complete pathological response rate was 29.4%,and the major pathological response rate was 55.9%.The incidence rate of grade 1-2 immune-related adverse events was 67.4%,and the incidence rate of grade 3 or above adverse events was 7.0%.Conclusions Neoadjuvant PD-1 inhibitor combined with chemotherapy for non-small cell lung cancer has significant efficacy,with high rates of pathological response and R0 resection.The immune-related adverse events and surgical complications are within an acceptable range,indicating high safety.
作者
李铁铮
胥凯凯
邓钰卿
王沛豪
秦齐
郭康顺
王炳仁
常栋
崔永
Li Tiezheng;Xu Kaikai;Deng Yuqing;Wang Peihao;Qin Qi;Guo Kangshun;Wang Bingren;Chang Dong;Cui Yong(Department of Thoracic Surgery,Beijing Friendship Hospital,Capital Medical University,Beijing 100050,China)
出处
《首都医科大学学报》
CAS
北大核心
2024年第4期636-641,共6页
Journal of Capital Medical University
基金
首都卫生发展科研专项项目(2022-2-2024)。
